{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T17:53:40Z","timestamp":1717178020225},"reference-count":38,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,10,15]]},"DOI":"10.2169\/internalmedicine.9070-21","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T22:10:13Z","timestamp":1647641413000},"page":"3037-3044","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Caspofungin Treatment in Febrile Neutropenic Patients with Hematological Disorders: A Multicenter Consecutive Case Series"],"prefix":"10.2169","volume":"61","author":[{"given":"Kazuhiro","family":"Itoh","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, National Hospital Organization Awara Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Shigemi","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Hematology, Red Cross Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Tsukasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Red Cross Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Red Cross Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Morinaga","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Fukui Prefectural Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Yoshio","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Kanazawa Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Fukui-ken Saiseikai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Hospital Organization Tsuruga Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, University of Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kume H, Yamazaki T, Togano T, et al. Epidemiology of visceral mycoses in autopsy cases in Japan: comparison of the data from 1989, 1993, 1997, 2001, 2005 and 2007 in Annual of Pathological Autopsy Cases in Japan. Med Mycol J 52: 117-127, 2011.","DOI":"10.3314\/jjmm.52.117"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Snarr BD, Qureshi ST, Sheppard DC. Immune recognition of fungal polysaccharides. J Fungi (Basel) 3: 47, 2017.","DOI":"10.3390\/jof3030047"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol 36: 1443-1453, 2018.","DOI":"10.1200\/JCO.2017.77.6211"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106: 2258-2266, 2006.","DOI":"10.1002\/cncr.21847"},{"key":"5","unstructured":"5. Japanese Society of Medical Oncology. Practical Guideline of Febrile Neutropenia (FN). 2nd ed. Nankodo, Tokyo, 2017."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yoshida M, Akiyama N, Fujita H, et al. Analysis of bacteremia\/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. Int J Hematol 93: 66-73, 2011.","DOI":"10.1007\/s12185-010-0746-y"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Chen K, Wang Q, Pleasants RA, et al. Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysis. BMC Infect Dis 17: 159, 2017.","DOI":"10.1186\/s12879-017-2263-6"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Bitar D, Lortholary O, Le Strat Y, et al. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis 20: 1149-1155, 2014.","DOI":"10.3201\/eid2007.140087"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 95: 644-650, 2010.","DOI":"10.3324\/haematol.2009.012054"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Pagano L, Caira M, Picardi M, et al. Invasive aspergillosis in patients with acute leukemia: update on morbidity and mortality - SEIFEM-C report. Clin Infect Dis 44: 1524-1525, 2007.","DOI":"10.1086\/517849"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis 46: 1813-1821, 2008.","DOI":"10.1086\/588660"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52: 427-431, 2011.","DOI":"10.1093\/cid\/ciq147"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Karimzadeh I, Farsaei S, Khalili H, Dashti-Khavidaki S. Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity? Expert Opin Drug Saf 11: 969-983, 2012.","DOI":"10.1517\/14740338.2012.721775"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Viscoli C, Castagnola E, Van Lint MT, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 32: 814-820, 1996.","DOI":"10.1016\/0959-8049(95)00619-2"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 108: 282-289, 2000.","DOI":"10.1016\/S0002-9343(99)00457-X"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135: 412-422, 2001.","DOI":"10.7326\/0003-4819-135-6-200109180-00010"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 67: 269-298, 2007.","DOI":"10.2165\/00003495-200767020-00009"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346: 225-234, 2002.","DOI":"10.1056\/NEJM200201243460403"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356: 348-359, 2007.","DOI":"10.1056\/NEJMoa061094"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356: 335-347, 2007.","DOI":"10.1056\/NEJMoa061098"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Vehreschild JJ, Birtel A, Vehreschild MJGT, et al. Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol 39: 310-324, 2013.","DOI":"10.3109\/1040841X.2012.711741"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Denning DW. Echinocandins: a new class of antifungal. J Antimicrob Chemother 49: 889-891, 2002.","DOI":"10.1093\/jac\/dkf045"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340: 764-771, 1999.","DOI":"10.1056\/NEJM199903113401004"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tamura K, Urabe A, Yoshida M, et al. Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. Leuk Lymphoma 50: 92-100, 2009.","DOI":"10.1080\/10428190802635500"},{"key":"25","unstructured":"25. National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events (CTCAE) v4.0 [Internet]. [cited 2021 Nov 22]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351: 1391-1402, 2004.","DOI":"10.1056\/NEJMoa040446"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Shibata Y, Miyahara Y, Sadaka Y, et al. Evaluation of the effectiveness of caspofungin against febrile neutropenia and the factors related to the alteration in its plasma concentration. J Infect Chemother 25: 801-805, 2019.","DOI":"10.1016\/j.jiac.2019.04.011"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Kanda Y. Investigation of the freely available easy-to-use software &apos;EZR&apos; for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. <i>In vivo<\/i> comparison of the pharmacodynamic targets for echinocandin drugs against <i>Candida<\/i> species. Antimicrob Agents Chemother 54: 2497-2506, 2010.","DOI":"10.1128\/AAC.01584-09"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Itoh K, Shigemi H, Chihara K, Sada K, Yamauchi T, Iwasaki H. Caspofungin suppresses zymosan-induced cytokine and chemokine release in THP-1 cells: possible involvement of the spleen tyrosine kinase pathway. Transl Res 227: 53-63, 2021.","DOI":"10.1016\/j.trsl.2020.07.005"},{"key":"31","unstructured":"31. Neuenschwander LC, Bittencourt H, Ribeiro AFT, et al. Plasma levels of procalcitonin and eight additional inflammatory molecules in febrile neutropenic patients. Clinics (Sao Paulo) 66: 1699-1705, 2011."},{"key":"32","unstructured":"32. Presterl E, Lassnigg A, Mueller-Uri P, El-Menyawi I, Graninger W. Cytokines in sepsis due to Candida albicans and in bacterial sepsis. Eur Cytokine Netw 10: 423-430, 1999."},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101: 1644-1655, 1992.","DOI":"10.1378\/chest.101.6.1644"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 103: 565-575, 1993.","DOI":"10.1378\/chest.103.2.565"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis. Arch Intern Med 167: 1655-1663, 2007.","DOI":"10.1001\/archinte.167.15.1655"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Kinoshita K, Iwasaki H, Uzui H, Ueda T. Candin family antifungal agent micafungin (FK463) modulates the inflammatory cytokine production stimulated by lipopolysaccharide in THP-1 cells. Transl Res 148: 207-213, 2006.","DOI":"10.1016\/j.trsl.2006.07.001"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Shibata Y, Hagihara M, Kato H, et al. Caspofungin versus micafungin in the incidence of hepatotoxicity in patients with normal to moderate liver failure. J Infect Chemother 23: 349-353, 2017.","DOI":"10.1016\/j.jiac.2017.02.008"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Yamashita C, Takesue Y, Matsumoto K, et al. Echinocandins versus non-echinocandins for empirical antifungal therapy in patients with hematological disease with febrile neutropenia: a systematic review and meta-analysis. J Infect Chemother 26: 596-603, 2020.","DOI":"10.1016\/j.jiac.2020.01.015"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/20\/61_9070-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T03:27:05Z","timestamp":1665804425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/20\/61_9070-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,15]]},"references-count":38,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9070-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,15]]},"article-number":"9070-21"}}